Navigation Links
Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass., April 13, 2007 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced today that results of preclinical studies with its lead product candidate, XMT-1001, will be presented in two posters at the 2007 Annual Meeting of the American Association of Cancer Research (AACR) taking place April 14-18th in Los Angeles, CA. Full text of the abstracts can be viewed online at the AACR website at http://www.AACR.org.

The presentation schedule is as follows:

Abstract #781 "XMT-1001, a novel polymeric prodrug of camptothecin, is a potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse model" will be presented in a poster session on Sunday, April 15th from 8:00 am - 12:00 pm. Alex Yurkovetskiy and Russell C. Petter are the presenting authors.

Abstract #4723 "Pharmacokinetics of a novel camptothecin conjugate (XMT- 1001) in the rat and dog" will be presented in a poster session on Tuesday, April 17th from 1:00 - 5:00 pm. Ullrich Schwertschlag and Alex Yurkovetskiy are the presenting authors.

About XMT-1101

XMT-1001 is Mersana's most advanced Fleximer(R)-based product candidate. It utilizes a novel, dual release mechanism to liberate a camptothecin prodrug, which is then converted within cells into camptothecin, a DNA topoisomerase I inhibitor. In preclinical studies, XMT-1001 was better tolerated and more efficacious than either camptothecin or irinotecan in models of human cancer, showing extended plasma half-life and high concentrations in tumor tissue.

About Fleximer Technology

Fleximer(R) technology improves the therapeutic index of cytotoxic compounds useful as anti-cancer agents by uniquely combining biodegradability with "biological stealth" properties, making Fleximer(R) materials and their conjugates long-circulating and non-immunotoxic. Fleximer(R) molecules are characterized
'"/>




Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/4/2015)... Rogne Bioscience, a privately-held biotechnology company developing ... and mechanism of action data will be presented during ... (SID) Annual Meeting being held May 6-9, 2015 at ... . Logo - http://photos.prnewswire.com/prnh/20150501/213318LOGO ... novel, low MW (<1700 daltons) peptide as a topical ...
(Date:5/4/2015)... , May 4, 2015  By looking at ... to distinguish between two very different conditions that ... Theodore Henderson , MD, PhD., a ... cases, this study can help the ... therefore treatment options, for Post-Traumatic Stress Disorder (PTSD) ...
(Date:5/4/2015)... 4, 2015  CytRx Corporation (Nasdaq: CYTR ... in oncology, today announced an interim analysis from ... pairing aldoxorubicin with either gemcitabine or ifosfamide. Both ... with escalating doses of aldoxorubicin. The combinations appear ... lowest dose level of aldoxorubicin (170 mg/m2), impressive ...
Breaking Medicine Technology:Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7
... HILL, N.J. and ATLANTA, Feb. 9, 2012  Glowpoint, Inc. ... provider of cloud managed video services , today ... a leader in designing and integrating operating rooms, has ... video platform for videoconferencing and broadcasting from operating rooms. ...
... Mylan Inc. (Nasdaq: MYL ) CEO Heather Bresch ... Commerce Committee at a hearing hosted by the subcommittee on ... User Fees and Further Examination of Drug Shortages." ... peace of mind in knowing that every prescription, brand or ...
Cached Medicine Technology:Stryker Communications Selects Glowpoint to Enhance IP Video Platform for Operating Rooms 2Stryker Communications Selects Glowpoint to Enhance IP Video Platform for Operating Rooms 3Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 2Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 3Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 4
(Date:5/4/2015)... In May of 2010, after two years ... In the wake of this tragedy, Ty’s parents Kirk and ... exposes the grim reality of bullying and its devastating consequences. ... and Laura to share their story and offer education and ... another family — a mission that took the Smalley family ...
(Date:5/4/2015)... The U.S. healthcare worker shortage crisis ... ranks of senior citizens (1) and 27 million Obamacare-insured ... healthcare system. Additionally, as older healthcare employees retire, there ... the U.S. Census Bureau, the number of American workers ... 2050 while those 25 to 54 will likely increase ...
(Date:5/4/2015)... Ticket Down is a reputable source for ... . While the World Cup is the most known ... years, the International Champions Cup is one of the biggest ... attendance record for soccer in the United States set when ... the University of Michigan. This year, the defending champion Manchester ...
(Date:5/4/2015)... OK and Seattle, WA (PRWEB) May 04, 2015 ... the formation of a collaboration to facilitate development of ... of ophthalmic disorders that lead to blindness, including Diabetic ... the MiDROPS™ formulation platform developed by EyeCRO, which can ... eye via a topical eyedrop. , Under the ...
(Date:5/4/2015)... Ticket Down is a reputable source for authentic ... in Charlottesville, VA. McCartney is one of the ... and this beloved performer continues to roll along with no ... two legendary groups: Wings and The Beatles, has been celebrating ... on the “Out There” tour and has continually added new ...
Breaking Medicine News(10 mins):Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2
... Feb. 3 BeneChill, Inc. ( www.benechill.com ) ... Intra-Nasal Cooling Effectiveness) study. This randomized study will ... during resuscitation increases patient resuscitation and survival rates.The ... approval study in Europe. The company received CE ...
... Nearly three out of four Americans (71 ... cost of addiction treatment - yet most consumers ... would pay for substance abuse treatment, according to ... Hazelden, the national nonprofit organization that helps people ...
... ESRX ), one of the largest pharmacy benefit management companies ... quarter earnings,on Wednesday, February 25, 2009 after the market closes ... results on Thursday,February 26, 2009, at 10:00 a.m. Eastern Time ... call is being webcast and can be accessed at Express ...
... be avoided since most symptoms fade within 6 weeks, ... A combination of physical therapy and anti-inflammatory drugs is ... by symptomatic lumbar degenerative disc disease, according to a ... found that in 90 percent of people with low ...
... known that patients with few primary care doctor,s office ... new research indicates that even patients who see their ... study, which appears in the February issue of ... a team of researchers at UC Davis, the University ...
... allied healthcare providers, and policymakers will gather in ... Williamsburg Lodge to learn practical, clinical information on ... and innovative translational research advances that impact patient ... full program, faculty, accreditation, and registration information is ...
Cached Medicine News:Health News:BeneChill Launches European Study of Intra-Arrest Cooling 2Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 2Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 3Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 4Health News:Express Scripts Announces Fourth Quarter 2008 Earnings Conference Call 2Health News:Therapy, Meds Best for Lumbar Low Back Pain 2Health News:Study shows that primary care doctors miss opportunities to recommend colon cancer screening 2Health News:Opinion Leaders in Women’s Health To Take the Podium at the 17th Annual Congress on Women’s Health 2
Titanium 0.18 mm diameter angled tip, 10 mm angled shaft. Used to mark the visual axis. Round knurled handle with dull finish. Overall length: 4.7 inches. Most popular size or model....
0.3 mm hook angled 45 degrees, 9 mm from tip to bend. Flat smooth handle with polished finish. Overall length: 4.6 inches....
Straight 31 mm shaft with flat handle and polished finish. 0.5 mm cup. Overall length: 5 inches....
Round knurled handle with adjustable finger-like tips that rest in the grooved disposable trephine blades. Used with disposable trephine blades. Polished finish. Most popular size or model....
Medicine Products: